Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

NCT02598661 is registered in ClinicalTrials.gov with Geron Corporation as lead sponsor.

NCT NCT02598661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02598661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Lead sponsor
Geron Corporation
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
January 12, 2016
Completion date
October 13, 2026
Enrollment
289 (actual)
Sites
126

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes